Network meta-analyses should be the highest level of evidence in treatment guidelines

European Archives of Psychiatry and Clinical Neuroscience

Volumn 266, Issue 6, 2016, Pages 477-480

  Leucht, Stefan ^a   Chaimani, Anna ^b   Cipriani, Andrea S ^c   Davis, John M ^d,e   Furukawa, Toshi A ^f   Salanti, Georgia ^g  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b UNIVERSITY OF IOANNINA   (Greece)

^c WARNEFORD HOSPITAL   (United Kingdom)

^d UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^e MARYLAND PSYCHIATRIC RESEARCH CENTER   (United States)

^f KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^g UNIVERSITY OF BERN   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; OLANZAPINE; QUETIAPINE; NEUROLEPTIC AGENT;

CLINICAL PRACTICE; DATA ANALYSIS; EDITORIAL; EVIDENCE BASED MEDICINE; HUMAN; META ANALYSIS (TOPIC); METHODOLOGY; PRACTICE GUIDELINE; PRIORITY JOURNAL; SYSTEMATIC REVIEW (TOPIC); MENTAL DISORDERS; NETWORK META-ANALYSIS; STANDARDS;

ANTIPSYCHOTIC AGENTS; EVIDENCE-BASED MEDICINE; GUIDELINES AS TOPIC; HUMANS; MENTAL DISORDERS; NETWORK META-ANALYSIS;

EID: 84978705088     PISSN: 09401334     EISSN: 14338491     Source Type: Journal    
DOI: 10.1007/s00406-016-0715-4     Document Type: Editorial

References (19)

1. Bastian H, Glasziou P, Chalmers I (2010) Seventy-five trials and eleven systematic reviews a day: How will we ever keep up? PLoS medicine 7:e1000326
2. Cipriani A, Furukawa TA, Salanti G, Geddes JR, Higgins JP, Churchill R, Watanabe N, Nakagawa A, Omori IM, McGuire H, Tansella M, Barbui C (2009) Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis. Lancet 373:746–758
3. Cipriani A, Higgins JP, Geddes JR, Salanti G (2013) Conceptual and technical challenges in network meta-analysis. Ann Intern Med 159:130–137
4. Dechartres A, Trinquart L, Boutron I, Ravaud P (2013) Influence of trial sample size on treatment effect estimates: meta-epidemiological study. BMJ 346:f2304
5. Evidence-Based Medicine Working G (1992) Evidence-based medicine. A new approach to teaching the practice of medicine. JAMA 268:2420–2425
6. Furukawa T (2004) Meta-analyses and megatrials: Neither is the infallible, universal standard. Evi Based Mental Health 7:34–35
7. Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, Schunemann HJ, Group GW (2008) Grade: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 336:924–926
8. Helfer B, Prosser A, Samara MT, Geddes JR, Cipriani A, Davis JM, Mavridis D, Salanti G, Leucht S (2015) Recent meta-analyses neglect previous systematic reviews and meta-analyses about the same topic: a systematic examination. BMC Med 13:82
9. Heres S, Davis J, Maino K, Jetzinger E, Kissling W, Leucht S (2006) Why olanzapine beats risperidone, risperidone beats quetiapine, and quetiapine beats olanzapine: an exploratory analysis of head-to-head comparison studies of second-generation antipsychotics. Am J Psychiatry 163:185–194
10. Lelorier J, Grégoire G, Benhaddad A, Lapierre J, Derderian F (1997) Discrepancies between meta-analyses and subsequent large randomized, controlled trials. N Engl J Med 337:536–542
11. Leucht S, Arbter D, Engel RR, Kissling W, Davis JM (2009) How effective are second-generation antipsychotic drugs? A meta-analysis of placebo-controlled trials. Mol Psychiatry 14:429–447
12. Leucht S, Cipriani A, Spineli L, Mavridis D, Orey D, Richter F, Samara M, Barbui C, Engel RR, Geddes JR, Kissling W, Stapf MP, Lassig B, Salanti G, Davis JM (2013) Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet 382:951–962
13. Leucht S, Corves C, Arbter D, Engel RR, Li C, Davis JM (2009) Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 373:31–41
14. Leucht S, Kissling W, Davis JM (2009) Second-generation antipsychotic drugs for schizophrenia: Can we resolve the conflict? Psychol Med 39:1591–1602
15. Leucht S, Komossa K, Rummel-Kluge C, Corves C, Hunger H, Schmid F, Schwarz S, Davis JM (2009) A meta-analysis of head to head comparisons of second generation antipsychotics in the treatment of schizophrenia. Am J Psychiatry 166:152–163
16. Rouse B, Cipriani A, Shi Q, Coleman AL, Dickersin K, Li T (2016) Network meta-analysis for clinical practice guidelines: a case study on first-line medical therapies for primary open-angle glaucoma. Ann Intern Med 164:674–682
17. Salanti G, Del Giovane C, Chaimani A, Caldwell DM, Higgins JP (2014) Evaluating the quality of evidence from a network meta-analysis. PLoS ONE 9:e99682
18. Shea BJ, Hamel C, Wells GA, Bouter LM, Kristjansson E, Grimshaw J, Henry DA, Boers M (2009) Amstar is a reliable and valid measurement tool to assess the methodological quality of systematic reviews. J Clin Epidemiol 62:1013–1020
19. Trikalinos TA, Churchill R, Ferri M, Leucht S, Tuunainen A, Wahlbeck K, Ioannidis JPA (2004) Effect sizes in cumulative meta-analyses of mental health randomized trials evolved over time. JClinEpidemiol 57:1124–1130